Tyrosine kinase inhibitors in treating soft tissue sarcomas: sunitinib in non-GIST sarcomas

Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical & translational oncology 2010-07, Vol.12 (7), p.468-472
Main Authors: Homet Moreno, Blanca, Garralda Cabanas, Elena, Hitt, Ricardo
Format: Article
Language:English
Subjects:
Antineoplastic Agents - therapeutic use
Educational Series
Gastrointestinal Stromal Tumors - drug therapy
Humans
Indoles - therapeutic use
Medicine
Medicine & Public Health
Oncology
Protein Kinase Inhibitors - therapeutic use
Protein-Tyrosine Kinases - antagonists & inhibitors
Pyrroles - therapeutic use
Sarcoma - drug therapy
Sarcoma - pathology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Sarcomas are uncommon malignancies that represent more than 50 different tumor types. Surgery remains the mainstay of treating localised disease. Anthracycline and ifosfamide-based chemotherapy is an option for advanced disease; however, effective treatment of advanced soft tissue sarcoma remains a challenge. Advances in understanding the genetic nature of cancer have led to the development of new treatment options for sarcoma. Sunitinib malate is an oral multitargeted tyrosine kinase inhibitor with antiangiogenic properties and promising activity in the treatment of GIST refractory to imatinib, however in either soft tissue sarcoma, experience with sunitinib is under development in different clinical trials. In this review we offer the experience with this small molecular target in non-GIST sarcomas.
ISSN:1699-048X
1699-3055
DOI:10.1007/s12094-010-0539-z